| Founded | 2006 |
|---|---|
| Closed | 2017 |
| Country | USA |
| Sector | Biotech |
| Collapse type | Regulatory Kill |
| Founder | Prabhavathi Fernandes |
Cempra
"A 7-3 FDA panel vote against their lead antibiotic sent Cempra into a terminal collapse."
Forced closure by regulatory action
Key Events Timeline
Cempra's antibiotic solithromycin (Solithera) received an FDA advisory panel rejection in November 2016 over hepatotoxicity concerns, with the committee voting 7-3 against approval.
// full analysis
Full analysis requires the Analyst plan
Documented cause · Market cycle · Competitive moat type · Verified lesson
€149/mo · or contribute your autopsy for free access →
UnicornBurn Season 0 opens July 2026. 10,000 founders competing in one world. Your startup fights for the market every Saturday. Most will end up here. Which one are you?
JOIN SEASON 0 →Cempra followed a documented pattern. Identify the same signals in any company before they reach the point of no return.
Witnessed a startup failure first-hand? Share the real story. First-hand accounts from founders and team members get prioritized for publication.
SUBMIT AN AUTOPSY →Failure intelligence for due diligence and risk analysis.
Structured dataset by collapse type, for 5031 startups. 7-day trial.
See plans →Free JSON API. No key required. 50 autopsies, 10 req/day.
Full dataset available with Intelligence plan API key. CORS enabled.
Explore API →Academic, press, or research use? Free JSON API available — no auth required →